EMA Authorised: Revinty Ellipta (fluticasone furoate;vilanterol trifenatate) — GlaxoSmithKline Trading Services Limited

View source ↗

Summary

EMA authorised Revinty Ellipta, an inhaled fixed-dose combination of fluticasone furoate and vilanterol trifenatate for asthma, marketed by GlaxoSmithKline Trad…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Fluticasone Furoate (fluticasone furoate)
• vilanterol trifenatate (vilanterol trifenatate)

Snippet

Status: Authorised. Therapeutic area: Asthma. MAH: GlaxoSmithKline Trading Services Limited. Decision date: 12/03/2025